Form 4: Cidara Therapeutics Director Ryan Spencer Reports Stock Option Grant
SEC Form 4 Filing
Director Ryan Spencer reports acquisition of stock options in Cidara Therapeutics.
Summary
- Ryan Spencer, a director of Cidara Therapeutics, Inc., reported a transaction on July 18, 2024.
- Spencer acquired 2,125 stock options with an exercise price of $12.64.
- These options vest on the earlier of the first anniversary of the grant date or the day prior to the Issuer's 2025 annual meeting of stockholders.
- Following the transaction, Spencer directly owns 2,125 derivative securities.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing. The sentiment is neutral as it simply reports a transaction.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This is a standard SEC Form 4 filing, which is common for corporate insiders reporting changes in their beneficial ownership of company securities. It's a routine part of corporate governance and transparency.
Stakeholder Impact
- The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 07/18/2024 | Date of transaction: Ryan Spencer acquired stock options. |
| 07/19/2024 | Date of filing: Form 4 filing date. |
| 07/17/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.